n(1), n(12)-diethylspermine profile

N(1),N(12)-diethylspermine is a synthetic polyamine analog of spermine. It has been shown to have a variety of biological effects, including inhibition of cell growth and induction of apoptosis. It is thought to exert its effects by interacting with polyamine transport systems and by modulating the activity of polyamine-dependent enzymes. N(1),N(12)-diethylspermine is also being investigated as a potential therapeutic agent for the treatment of cancer. It has been shown to be effective in inhibiting the growth of a variety of cancer cell lines, both in vitro and in vivo. The compound is of interest to researchers because it may be able to inhibit cancer cell growth in ways that are not possible with traditional chemotherapeutic agents. The compound is synthesized using a variety of chemical reactions, and its effects are being studied in animal models and human cell cultures. The compound is also being studied as a possible therapeutic agent for other diseases, such as Alzheimer's disease and Parkinson's disease.'

N(1), N(12)-diethylspermine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N(1),N(12)-diethylspermine : A substituted spermine that is spermine in which a hydrogen attached to each of the primary amino groups has been replaced by an ethyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	4283
CHEMBL ID	18794
CHEBI ID	90282
SCHEMBL ID	7092466
MeSH ID	M0149287

Synonym
BIO1_000372 ,
tocris-0500
NCGC00024618-01
BIO1_001350
BIO1_000861
be-3-4-3
1,12-besm
n(1), n(12)-diethylspermine
1,4-butanediamine, n,n'-bis(3-(ethylamino)propyl)-
n(1),n(12)-bis(ethyl)spermine
n(1),n(12)-diethylspermine
chebi:90282 ,
CHEMBL18794
bis(ethyl)spermine
61345-84-4
n,n'-bis[3-(ethylamino)propyl]butane-1,4-diamine
3xxe6arw3h ,
unii-3xxe6arw3h
3,7,12,16-tetraazaoctadecane
SCHEMBL7092466
n1,n12-bis(ethyl)spermine
n1,n12-diethylspermine
n1,n1'-(butane-1,4-diyl)bis(n3-ethylpropane-1,3-diamine)
Q27162447
1,12-bisethylamino-4,9-diazadodecane
1,4-butanediamine n1,n4-bis(3-(ethylamino)propyl)-
de-343
n~1~,n~4~-bis[3-(ethylamino)propyl]butane-1,4-diamine
DTXSID50976862

Excerpt	Relevance	Reference
" Detailed studies with estrogen receptor-positive MCF-7 and estrogen receptor- negative Hs578t cells show a similar dose-response curve with concentrations of 1-10 microM resulting in maximal growth inhibition."	( Growth inhibition of hormone-responsive and -resistant human breast cancer cells in culture by N1, N12-bis(ethyl)spermine. Bergeron, RJ; Casero, RA; Davidson, NE; Mank, AR; Prestigiacomo, LJ, 1993)	0.29
" On the basis of subcutaneous dose-response data and toxicity profiles, two compounds, N(1),N(12)-diisopropylspermine and N(1),N(12)-diethylspermine, were taken forward into more complete evaluation."	( Polyamine analogue antidiarrheals: a structure-activity study. Algee, SE; Bergeron, RJ; Fannin, TL; McManis, JS; Slusher, MA; Smith, RE; Snyder, PS; Weimar, WR; Wiegand, J, 2001)	0.31

Role	Description
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
substituted spermine
tetramine	Any polyamine that contains four amino groups.
polyazaalkane	Any azaalkane in which two or more carbons in the chain are replaced by nitrogen.
secondary amino compound	A compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
TDP1 protein	Homo sapiens (human)	Potency	4.5339	0.0008	11.3822	44.6684	AID686978; AID686979
cytochrome P450 2C19 precursor	Homo sapiens (human)	Potency	12.5893	0.0025	5.8400	31.6228	AID899
Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)	Potency	15.8489	0.3162	12.7657	31.6228	AID881
Histamine H2 receptor	Cavia porcellus (domestic guinea pig)	Potency	15.8489	0.0063	8.2350	39.8107	AID881
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
lipid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
phospholipid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
apoptotic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell population proliferation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of macrophage derived foam cell differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonic acid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell migration	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
prostate gland development	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
regulation of epithelial cell differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of chemokine production	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of keratinocyte differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell cycle	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of growth	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
hepoxilin biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
endocannabinoid signaling pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cannabinoid biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipoxin A4 biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleic acid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipid oxidation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipoxygenase pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
iron ion binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
calcium ion binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
protein binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipid binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleate 13S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonate 8(S)-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonate 15-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleate 9S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytosol	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytoskeleton	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
plasma membrane	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
adherens junction	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
focal adhesion	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
membrane	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
extracellular exosome	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (187)

Assay ID	Title	Year	Journal	Article
AID214255	Growth inhibitory activity was measured for human U251MG NCI tumor cell line.	1998	Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24	Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines.
AID227460	Percent reduction was determined by using the ratio of mean of treated animal to that of control animal at a dose of 9.4 mg/kg	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID243322	Effect on Ornithine Decarboxylase (ODC) activity in L1210 cells at 1 uM for 4 hr	2005	Journal of medicinal chemistry, May-05, Volume: 48, Issue:9	Synthesis and biological evaluation of aminopolyamines.
AID220854	MESPM/MEHSPH Distribution in liver was determined after DESPM dosing of 6.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-27 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID220969	putrescine Distribution in kidney was determined after DESPM dosing of 8.0 mg/kg/day for 4.5 days in dog and sacrificed at 10 days PLD(cu dose-36 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID80967	Inhibitory concentration against growth of cultured HL-60 cells at 72 hrs.	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID218618	Spermine Distribution in kidney was determined after DESPM dosing of 4 mg/kg/day for 13 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-52 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID218612	Spermidine Distribution in liver was determined after DESPM dosing of 8.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-36 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID220984	Spermidine Distribution in kidney was determined after DESPM dosing of 1.87 mg/kg/day for 28 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-52.4 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID118533	Mean survival of mice with L1210 leukemia was evaluated on day 60 at 20 mg/kg by ip administration (schedule: Q8H,1-3days)	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID220844	MESPM/MEHSPH Distribution in kidney was determined after DESPM dosing of 6.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-27 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID218607	Spermidine Distribution in liver was determined after DESPM dosing of 1.87 mg/kg/day for 28 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-52.4 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID98920	Inhibitory concentration against L1210 cells on 96h incubation.	1995	Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13	The role of charge in polyamine analogue recognition.
AID169976	Compound was evaluated for agonist activity at 1 uM exhibiting moderate antagonism of [3H]MK-801 binding relative to 100% control	1995	Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3	Impact of polyamine analogues on the NMDA receptor.
AID220979	putrescine Distribution in liver was determined after DESPM dosing of 8.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-36 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID26614	Acid base constant value for N1 atom	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Polyamine analogue regulation of NMDA MK-801 binding: a structure-activity study.
AID118528	Mean survival of L1210 leukemic mice was evaluated on day 60 at 15 mg/kg by ip administration (schedule: Q8H,1-6days)	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID80491	In Vitro Activity of Compound Against H157 non-small-cell lung tumor line (non-SCLC) cultures.	2001	Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1	Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID235283	Ratio of survivors to the total mice in the test group; 0/6	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID150568	Inhibition of ornithine decarboxylase (ODC) activity	1994	Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21	Antiproliferative properties of polyamine analogues: a structure-activity study.
AID97319	Percent of clonogenic L1210 cells to relative to control was determined after the treatment with the compound of 10 uM was for 96h	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID243356	Effect on Spermidine/spermine N1-acetyl transferase (SSAT) activity in L1210 cells at 10 uM for 48h	2005	Journal of medicinal chemistry, May-05, Volume: 48, Issue:9	Synthesis and biological evaluation of aminopolyamines.
AID78587	Cytokinetic effects on H82 small-cell lung tumor line (SCLC) after 96-h treatment; Cytostatic at <= 10 uM	2001	Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1	Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID250132	Effect on spermine (SPM) levels after 48 h treatment at 150 uM in L1210 cells	2005	Journal of medicinal chemistry, May-05, Volume: 48, Issue:9	Synthesis and biological evaluation of aminopolyamines.
AID223880	Weight loss of rat over the 6-h experimental period when a dose of 14.3 mg/kg (35.4 administered	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID248014	Inhibitory concentration against growth of murine L1210 cells at 96 hours	2005	Journal of medicinal chemistry, Jun-16, Volume: 48, Issue:12	Polyamine-vectored iron chelators: the role of charge.
AID80498	Effect of 10 uM of compound on NCI H157 cell lines was assessed from the amount of spermine (values in parentheses are those in the absence of compound)	2001	Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1	Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID78592	Effect of 10 uM of compound on NCI H82 cell lines was assessed from the amount of putrescine (values in parentheses are those in the absence of compound)	2001	Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1	Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID220963	putrescine Distribution in kidney was determined after DESPM dosing of 1.87 mg/kg/day for 28 days in dog and sacrificed at 10 days PLD(cu dose-52.4 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID220991	Spermidine Distribution in kidney was determined after DESPM dosing of 8.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-36 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID98380	In vitro inhibition of L1210 growth after 96 hours.	1994	Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21	Antiproliferative properties of polyamine analogues: a structure-activity study.
AID218628	Spermine Distribution in liver was determined after DESPM dosing of 4 mg/kg/day for 13 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-52 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID8694	Growth inhibitory activity was measured for human A549 tumor cell line.	1998	Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24	Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines.
AID44520	The chronic toxicity was determined in female CD1 mice after (ip) administration	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID218627	Spermine Distribution in liver was determined after DESPM dosing of 1.87 mg/kg/day for 28 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-52.4 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID221558	% increase in life span in L1210 leukemic mice was calculated at 10 mg/kg by ip administration	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID223710	Stool output of rat over the 6-h collection period when a dose of 4.7 mg/kg (11.6 administered	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID99108	Compound was evaluated for its impact on putrescine (Put) levels after 48 hr at concentration 30 uM	1994	Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21	Antiproliferative properties of polyamine analogues: a structure-activity study.
AID220841	MESPM/MEHSPH Distribution in kidney was determined after DESPM dosing of 1.87 mg/kg/day for 28 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-52.4 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID235279	Ratio of survivors to the total mice in the test group; 0/47	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID226163	Stool output of rat over the 6-h collection period when a dose of 0 mg/kg (0 administered	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID97317	Percent of clonogenic L1210 cells to relative to control was determined after the treatment with the compound of 10 uM was for 48 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID227454	Percent reduction was determined by using the ratio of mean of treated animal to that of control animal at a dose of 4.7 mg/kg	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID103583	Growth inhibitory activity was measured for human MCF-7 tumor cell line.	1998	Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24	Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines.
AID223719	Stool output of rat over the 6-h collection period when a dose of 9.4 mg/kg (23.3 administered	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID220851	MESPM/MEHSPH Distribution in liver was determined after DESPM dosing of 1.87 mg/kg/day for 28 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-52.4 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID83766	Growth inhibitory activity was measured for human HT-29 tumor cell line.	1998	Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24	Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines.
AID26648	Acid base constant value for N2 atom	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Polyamine analogue regulation of NMDA MK-801 binding: a structure-activity study.
AID218619	Spermine Distribution in kidney was determined after DESPM dosing of 4 mg/kg/day for 13 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-52 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID218629	Spermine Distribution in liver was determined after DESPM dosing of 4 mg/kg/day for 13 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-52 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID199308	Inhibition of S-Adenosyl-methionine decarboxylase (AdoMetDC) activity	1994	Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21	Antiproliferative properties of polyamine analogues: a structure-activity study.
AID169975	Compound was evaluated for agonist activity at 10 uM exhibiting moderate antagonism of [3H]MK-801 binding relative to 100% control	1995	Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3	Impact of polyamine analogues on the NMDA receptor.
AID220842	MESPM/MEHSPH Distribution in kidney was determined after DESPM dosing of 4 mg/kg/day for 13 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-52 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID199768	Impact on polyamine biosynthetic enzyme, S-adenosyl-L-methionine decarboxylase in L1210 cells treated with the compound for 6 hr.	1995	Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13	The role of charge in polyamine analogue recognition.
AID78591	Effect of 10 uM of compound on NCI H82 cell lines was assessed from the amount of SSAT (values in parentheses are those in the absence of compound)	2001	Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1	Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID78593	Effect of 10 uM of compound on NCI H82 cell lines was assessed from the amount of spermidine (values in parentheses are those in the absence of compound)	2001	Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1	Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID119224	Ratio of survivors to the total mice in the test group; 0/13	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID250160	Effect on Putrescine (PUT) levels after 48 hr treatment at 150 uM in L1210 cells	2005	Journal of medicinal chemistry, May-05, Volume: 48, Issue:9	Synthesis and biological evaluation of aminopolyamines.
AID97891	In vitro inhibition of uptake [3H]-spermidine in L1210 (murine leukemia) cells.	1996	Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13	Metabolically programmed polyamine analogue antidiarrheals.
AID220988	Spermidine Distribution in kidney was determined after DESPM dosing of 6.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-27 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID212008	The chronic lethal dose administered as intraperitoneal injection in mice	1997	Journal of medicinal chemistry, May-09, Volume: 40, Issue:10	A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.
AID201172	Effect of 10 uM on spermine/spermidine-N-acetyltransferase (SSAT) induction in non-SCLC cells	2001	Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1	Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID218631	Spermine Distribution in liver was determined after DESPM dosing of 6.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-27 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID218609	Spermidine Distribution in liver was determined after DESPM dosing of 4 mg/kg/day for 13 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-52 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID212006	The acute lethal dose administered as a single intraperitoneal injection in mice	1997	Journal of medicinal chemistry, May-09, Volume: 40, Issue:10	A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.
AID220853	MESPM/MEHSPH Distribution in liver was determined after DESPM dosing of 4 mg/kg/day for 13 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-52 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID220989	Spermidine Distribution in kidney was determined after DESPM dosing of 6.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-27 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID118529	Mean survival of mice with 10e 5 L1210 cells was evaluated on day 60 at 15 mg/kg by ip administration (schedule: Q12H,1-6days)	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID200225	Inhibition of Inhibition of rat liver form of S-adenosyl-methionine decarboxylase enzyme (AdoMet-DC)	2001	Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1	Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID252378	Intracellular concentration was determined in murine L1210 cells after treatment with 30 uM compound for 48 h	2005	Journal of medicinal chemistry, Jun-16, Volume: 48, Issue:12	Polyamine-vectored iron chelators: the role of charge.
AID250162	Effect on spermidine (SPD) levels after 48 hr treatment at 150 uM in L1210 cells	2005	Journal of medicinal chemistry, May-05, Volume: 48, Issue:9	Synthesis and biological evaluation of aminopolyamines.
AID99124	Compound was evaluated for its impact on spermidine levels after 48 hr at concentration 30 uM	1994	Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21	Antiproliferative properties of polyamine analogues: a structure-activity study.
AID96691	Impact (30 uM) on polyamine(Spd) pools in L1210 cells, expressed relative to untreated controls (control = 100%).	1995	Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13	The role of charge in polyamine analogue recognition.
AID218606	Spermidine Distribution in liver was determined after DESPM dosing of 1.87 mg/kg/day for 28 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-52.4 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID80966	Inhibitory concentration against growth of cultured HL-60 cells at 144 hrs.	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID96489	Compound was evaluated for its impact on spermine levels after 48 hr at concentration 30 uM	1994	Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21	Antiproliferative properties of polyamine analogues: a structure-activity study.
AID96692	Impact (30 uM) on polyamine(Spm) pools in L1210 cells, expressed relative to untreated controls (control = 100%).	1995	Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13	The role of charge in polyamine analogue recognition.
AID112599	% increase in life span in L1210 leukemic mice was calculated at 20 mg/kg by ip administration	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID80497	Effect of 10 uM of compound on NCI H157 cell lines was assessed from the amount of spermidine (values in parentheses are those in the absence of compound)	2001	Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1	Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID227450	Percent reduction was determined by using the ratio of mean of treated animal to that of control animal at a dose of 23.5 mg/kg	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID80494	Cytokinetic effect on H157 non-small-cell lung tumor line (non-SCLC) after 96-h treatment; Cytotoxic at <10 uM	2001	Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1	Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID218623	Spermine Distribution in kidney was determined after DESPM dosing of 8.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-36 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID220845	MESPM/MEHSPH Distribution in kidney was determined after DESPM dosing of 6.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-27 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID99103	Compound was evaluated for its impact on putrescine (Put) levels after 48 hr at concentration 150 uM	1994	Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21	Antiproliferative properties of polyamine analogues: a structure-activity study.
AID218632	Spermine Distribution in liver was determined after DESPM dosing of 8.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-36 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID80495	Effect of 10 uM of compound on NCI H157 cell lines was assessed from the amount of SSAT (values in parentheses are those in the absence of compound)	2001	Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1	Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID220977	putrescine Distribution in liver was determined after DESPM dosing of 6.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-27 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID220967	putrescine Distribution in kidney was determined after DESPM dosing of 6.0 mg/kg/day for 4.5 days in dog and sacrificed at 10 days PLD(cu dose-27 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID220840	MESPM/MEHSPH Distribution in kidney was determined after DESPM dosing of 1.87 mg/kg/day for 28 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-52.4 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID244579	Ability to compete with [3H]SPD for the polyamine transport apparatus in L1210 cells	2005	Journal of medicinal chemistry, Jun-16, Volume: 48, Issue:12	Polyamine-vectored iron chelators: the role of charge.
AID220852	MESPM/MEHSPH Distribution in liver was determined after DESPM dosing of 4 mg/kg/day for 13 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-52 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID98502	Tested for inhibition of L1210 cell growth by the compound after 48 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID99141	Compound was evaluated for its impact on spermine levels after 48 hr at concentration 150 uM	1994	Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21	Antiproliferative properties of polyamine analogues: a structure-activity study.
AID218617	Spermine Distribution in kidney was determined after DESPM dosing of 1.87 mg/kg/day for 28 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-52.4 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID227456	Percent reduction was determined by using the ratio of mean of treated animal to that of control animal at a dose of 47 mg/kg	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID26863	Acid base constant value for N3 atom	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Polyamine analogue regulation of NMDA MK-801 binding: a structure-activity study.
AID220850	MESPM/MEHSPH Distribution in liver was determined after DESPM dosing of 1.87 mg/kg/day for 28 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-52.4 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID227461	Percent reduction was determined by using the ratio of mean of treated animal to that of control animal at a dose of 94 mg/kg	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID218608	Spermidine Distribution in liver was determined after DESPM dosing of 4 mg/kg/day for 13 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-52 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID220990	Spermidine Distribution in kidney was determined after DESPM dosing of 8.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-36 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID147601	Inhibition of ornithine decarboxylase (ODC)	2001	Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1	Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID44519	The acute toxicity was determined in female CD1 mice after (ip) administration	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID248013	Inhibitory concentration against growth of murine L1210 cells at 48 hours	2005	Journal of medicinal chemistry, Jun-16, Volume: 48, Issue:12	Polyamine-vectored iron chelators: the role of charge.
AID421188	Antitumor activity against mouse L1210 cells	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Recent advances in the development of polyamine analogues as antitumor agents.
AID96690	Impact (30 uM) on polyamine(Put) pools in L1210 cells, expressed relative to untreated controls (control = 100%).	1995	Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13	The role of charge in polyamine analogue recognition.
AID220985	Spermidine Distribution in kidney was determined after DESPM dosing of 1.87 mg/kg/day for 28 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-52.4 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID218633	Spermine Distribution in liver was determined after DESPM dosing of 8.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-36 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID253111	Cellular concentration expressed in L1210 cells	2005	Journal of medicinal chemistry, May-05, Volume: 48, Issue:9	Synthesis and biological evaluation of aminopolyamines.
AID220986	Spermidine Distribution in kidney was determined after DESPM dosing of 4 mg/kg/day for 13 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-52 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID249436	Ratio of intracellular concentration to that of treatment concentration in L1210 cells	2005	Journal of medicinal chemistry, Jun-16, Volume: 48, Issue:12	Polyamine-vectored iron chelators: the role of charge.
AID220978	putrescine Distribution in liver was determined after DESPM dosing of 6.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-27 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID99119	Compound was evaluated for its impact on spermidine levels after 48 hr at concentration 150 uM	1994	Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21	Antiproliferative properties of polyamine analogues: a structure-activity study.
AID235280	Ratio of survivors to the total mice in the test group; 0/8	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID220966	putrescine Distribution in kidney was determined after DESPM dosing of 4.0 mg/kg/day for 13 days in dog and sacrificed at 75 days PLD(cu dose-52 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID218611	Spermidine Distribution in liver was determined after DESPM dosing of 6.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-27 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID203886	Inhibition of spermidine/spermine N1-Acetyltransferase (SSAT) activity	1994	Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21	Antiproliferative properties of polyamine analogues: a structure-activity study.
AID223873	Weight loss of rat over the 6-h experimental period when a dose of 0 mg/kg (0 administered	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID118534	Mean survival of mice with L1210 leukemia was evaluated on day 60 at 20 mg/kg by ip administration (schedule: Q8H,1-4days)	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID247622	Inhibitory activity against L1210 cell growth for 96h	2005	Journal of medicinal chemistry, May-05, Volume: 48, Issue:9	Synthesis and biological evaluation of aminopolyamines.
AID118535	Mean survival of mice with L1210 leukemia was evaluated on day 60 with no treatment	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID97365	Compound level in L1210 cells after 48 hours of incubation at initial concentration of 30 uM is expressed as nmol/10e6 cells	1994	Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21	Antiproliferative properties of polyamine analogues: a structure-activity study.
AID226169	Stool output of rat over the 6-h collection period when a dose of 14.3 mg/kg (35.4 administered	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID218622	Spermine Distribution in kidney was determined after DESPM dosing of 8.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-36 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID235278	Ratio of survivors to the total mice in the test group; 0/4	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID112600	% increase in life span in mice was calculated at 5 mg/kg by ip administration	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID220964	putrescine Distribution in kidney was determined after DESPM dosing of 1.87 mg/kg/day for 28 days in dog and sacrificed at 75 days PLD(cu dose-52.4 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID218630	Spermine Distribution in liver was determined after DESPM dosing of 6.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-27 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID98379	In vitro inhibition of L1210 growth after 48 hours.	1994	Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21	Antiproliferative properties of polyamine analogues: a structure-activity study.
AID220970	putrescine Distribution in kidney was determined after DESPM dosing of 8.0 mg/kg/day for 4.5 days in dog and sacrificed at 75 days PLD(cu dose-36 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID220959	MESPM/MEHSPH Distribution in liver was determined after DESPM dosing of 6.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-27 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID218621	Spermine Distribution in kidney was determined after DESPM dosing of 6.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-27 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID203868	Impact on polyamine biosynthetic enzyme Spermidine N-acetyl-transferase in L1210 cells treated with the compound for 48 hr.	1995	Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13	The role of charge in polyamine analogue recognition.
AID218613	Spermidine Distribution in liver was determined after DESPM dosing of 8.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-36 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID220960	MESPM/MEHSPH Distribution in liver was determined after DESPM dosing of 8.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-36 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID80489	Cytotoxicity against NCI H157 cell lines	2001	Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1	Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID220843	MESPM/MEHSPH Distribution in kidney was determined after DESPM dosing of 4 mg/kg/day for 13 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-52 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID243351	Effect on S-Adenosyl-methionine decarboxylase (AdoMetDC) activity in L1212 cells at 1 uM for 6 hr	2005	Journal of medicinal chemistry, May-05, Volume: 48, Issue:9	Synthesis and biological evaluation of aminopolyamines.
AID118532	Mean survival of mice with L1210 leukemia was evaluated on day 60 at 17.5 mg/kg by ip administration (schedule: Q8H,1-6days)	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID218626	Spermine Distribution in liver was determined after DESPM dosing of 1.87 mg/kg/day for 28 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-52.4 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID78594	Effect of 10 uM of compound on NCI H82 cell lines was assessed from the amount of spermine (values in parentheses are those in the absence of compound)	2001	Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1	Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID227448	Percent reduction was determined by using the ratio of mean of treated animal to that of control animal at a dose of 14.3 mg/kg	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID220965	putrescine Distribution in kidney was determined after DESPM dosing of 4.0 mg/kg/day for 13 days in dog and sacrificed at 10 days PLD(cu dose-52 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID218616	Spermine Distribution in kidney was determined after DESPM dosing of 1.87 mg/kg/day for 28 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-52.4 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID26881	Acid base constant value for N4 atom	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Polyamine analogue regulation of NMDA MK-801 binding: a structure-activity study.
AID220961	MESPM/MEHSPH Distribution in liver was determined after DESPM dosing of 8.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-36 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID97316	Percent of clonogenic L1210 cells to relative to control was determined after the treatment with the compound of 10 uM was for 24 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID220975	putrescine Distribution in liver was determined after DESPM dosing of 4 mg/kg/day for 13 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-52 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID220980	putrescine Distribution in liver was determined after DESPM dosing of 8.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-36 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID55811	Growth inhibitory activity was measured for human DU145 tumor cell line.	1998	Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24	Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines.
AID156179	Growth inhibitory activity was measured for human PC-3 tumor cell line.	1998	Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24	Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines.
AID227462	Percent reduction was determined by using the ratio of mean of treated animal to that of control animal at a dose of 94 mg/kg	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID247621	Inhibitory activity against L1210 cell growth for 48 hr	2005	Journal of medicinal chemistry, May-05, Volume: 48, Issue:9	Synthesis and biological evaluation of aminopolyamines.
AID68930	Concentration required to produce a 50% reduction in the uptake of [3H]TdR, by F98 glioma cells	1997	Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24	Boron-containing polyamines as DNA targeting agents for neutron capture therapy of brain tumors: synthesis and biological evaluation.
AID97887	Inhibition of radiolabeled spermidine uptake into L1210 cells in vitro.	1994	Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21	Antiproliferative properties of polyamine analogues: a structure-activity study.
AID220847	MESPM/MEHSPH Distribution in kidney was determined after DESPM dosing of 8.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-36 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID220974	putrescine Distribution in liver was determined after DESPM dosing of 1.87 mg/kg/day for 28 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-52.4 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID80496	Effect of 10 uM of compound on NCI H157 cell lines was assessed from the amount of putrescine (values in parentheses are those in the absence of compound)	2001	Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1	Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID221559	% increase in life span in mice was calculated at 15 mg/kg by ip administration	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID118531	Mean survival of mice with L1210 leukemia was evaluated on day 60 at 10 mg/kg by ip administration (schedule: Q8H,1-6days)	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID220968	putrescine Distribution in kidney was determined after DESPM dosing of 6.0 mg/kg/day for 4.5 days in dog and sacrificed at 75 days PLD(cu dose-27 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID150572	Impact on polyamine biosynthetic enzyme, Ornithine decarboxylase in L1210 cells treated with the compound for 4 hr.	1995	Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13	The role of charge in polyamine analogue recognition.
AID223902	Weight loss of rat over the 6-h experimental period when a dose of 9.4 mg/kg (23.3 administered	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID112598	% increase in life span in L1210 leukemic mice was calculated at 17.5 mg/kg by ip administration	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID97540	Level (30 uM) in L1210 cells.	1995	Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13	The role of charge in polyamine analogue recognition.
AID97892	Concentration inhibiting radiolabeled spermidine transport in L1210 cells.	1995	Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13	The role of charge in polyamine analogue recognition.
AID220973	putrescine Distribution in liver was determined after DESPM dosing of 1.87 mg/kg/day for 28 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-52.4 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID223893	Weight loss of rat over the 6-h experimental period when a dose of 4.7 mg/kg (11.6 administered	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID235281	Ratio of survivors to the total mice in the test group; 4/8	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID235277	Ratio of survivors to the total mice in the test group; 0/10	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID97362	Compound level in L1210 cells after 48 hours of incubation at initial concentration of 150 uM is expressed as nmol/10e6 cells	1994	Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21	Antiproliferative properties of polyamine analogues: a structure-activity study.
AID80355	Effect of exposure of H157 non-SCLC (<10 uM) for 96-h, and accumulation of compound was determined	2001	Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1	Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID218610	Spermidine Distribution in liver was determined after DESPM dosing of 6.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-27 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID63578	Inhibitory concentration against growth of cultured duadi cells at 144 hrs.	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID220976	putrescine Distribution in liver was determined after DESPM dosing of 4 mg/kg/day for 13 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-52 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID63579	Inhibitory concentration against growth of cultured duadi cells at 72 hrs.	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID80470	Effect of exposure of H157 non-SCLC to compound (<10 uM) for 96-h, on natural polyamines and accumulation of the compound; Decrease	2001	Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1	Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID112597	% increase in life span in L1210 leukemic mice was calculated at 15 mg/kg by ip administration	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID244574	Ability to inhibit [3H]SPD transport by L1210 cells	2005	Journal of medicinal chemistry, May-05, Volume: 48, Issue:9	Synthesis and biological evaluation of aminopolyamines.
AID98503	Tested for inhibition of L1210 cell growth by the compound after 96 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID218620	Spermine Distribution in kidney was determined after DESPM dosing of 6.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-27 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID97318	Percent of clonogenic L1210 cells to relative to control was determined after the treatment with the compound of 10 uM was for 72 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID220987	Spermidine Distribution in kidney was determined after DESPM dosing of 4 mg/kg/day for 13 days in dog(cu dose-52.4) and sacrificed at 75 days PLD(cu dose-52 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID235282	Ratio of survivors to the total mice in the test group; 9/16	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID220846	MESPM/MEHSPH Distribution in kidney was determined after DESPM dosing of 8.0 mg/kg/day for 4.5 days in dog(cu dose-52.4) and sacrificed at 10 days PLD(cu dose-36 mg/kg)	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Polyamine analogue antidiarrheals: a structure-activity study.
AID118530	Mean survival of mice with L1210 leukemia on day 60 at 5 mg/kg by ip administration (schedule: Q8H,1-6days)	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Synthetic polyamine analogues as antineoplastics.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	6 (12.00)	18.7374
1990's	32 (64.00)	18.2507
2000's	10 (20.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	2 (4.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	3 (5.88%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	48 (94.12%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
sym-homospermidine sym-homospermidine: analog of spermidine isolated from sandal leaves (Santalum album L.); structure. sym-homospermidine : A polyazaalkane comprising undecane with three aza groups placed at the 1-, 6- and 11-positions.	1.99	1	polyazaalkane; triamine
hydrogen carbonate Bicarbonates: Inorganic salts that contain the -HCO3 radical. They are an important factor in determining the pH of the blood and the concentration of bicarbonate ions is regulated by the kidney. Levels in the blood are an index of the alkali reserve or buffering capacity.. hydrogencarbonate : The carbon oxoanion resulting from the removal of a proton from carbonic acid.	1.98	1	carbon oxoanion	cofactor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
putrescine [no description available]	2.9	4	alkane-alpha,omega-diamine	antioxidant; fundamental metabolite
spermidine [no description available]	3.37	7	polyazaalkane; triamine	autophagy inducer; fundamental metabolite; geroprotector
spermine [no description available]	6.05	38	polyazaalkane; tetramine	antioxidant; fundamental metabolite; immunosuppressive agent
deferiprone Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.. deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.	2.02	1	4-pyridones	iron chelator; protective agent
eflornithine Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.. eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.	2.89	4	alpha-amino acid; fluoroamino acid	trypanocidal drug
entinostat [no description available]	3.14	1	benzamides; carbamate ester; primary amino compound; pyridines; substituted aniline	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
n(1),n(11)-diethylnorspermine N(1),N(11)-diethylnorspermine: structure given in first source	5.21	9
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	3.14	1	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
thymidine [no description available]	1.98	1	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
dipropylenetriame N-(3-aminopropyl)-1,3-propanediamine: structure in first source	1.99	1	polyazaalkane	algal metabolite; plant metabolite
leucine Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.	1.98	1	amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
cycloheximide Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.	1.98	1	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor
melarsen oxide melarsen oxide: inhibits glutathione reductase	3.1	1
glutamic acid Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.	1.99	1	glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical
nigericin Nigericin: A polyether antibiotic which affects ion transport and ATPase activity in mitochondria. It is produced by Streptomyces hygroscopicus. (From Merck Index, 11th ed). nigericin : A polyether antibiotic which affects ion transport and ATPase activity in mitochondria. It is produced by Streptomyces hygroscopicus.	1.98	1	polycyclic ether	antibacterial agent; antimicrobial agent; bacterial metabolite; potassium ionophore
n(1),n(14)-bis(ethyl)homospermine N(1),N(14)-bis(ethyl)homospermine: structure given in first source; depletes polyamines and inhibits the growth of tumor cells in tissue culture	5.3	10
mdl 27695 MDL 27695: structure given in first source	4.04	2
norspermine 3,3,3-tetramine : A polyazaalkane consisting of a 13-membered straight chain alkane with aza-groups at the 1-, 5-, 9- and 13-positions.	1.99	1	polyazaalkane; tetramine
s-adenosyl-3-thio-1,8-diaminooctane S-adenosyl-3-thio-1,8-diaminooctane: structure given in first source	3.1	1
n(1),n(8)-diethylspermidine N(1),N(8)-diethylspermidine: regulator of ornithine decarboxylase	4.18	5
s-(5'-deoxyadenosyl-5')-s-methylthioethylhydroxylamine S-(5'-deoxyadenosyl-5')-S-methylthioethylhydroxylamine: structure given in first source	1.98	1
4-boronophenylalanine 4-boronophenylalanine: neutron absorbing (10)B-cpd used in thermal neutron capturetherapy of malignant melanoma; RN given refers to (L)-isomer; structure given in first source	1.99	1
be 4-4-4-4 BE 4-4-4-4: structure given in first source	3.52	2
trichostatin a trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES	3.14	1	antibiotic antifungal agent; hydroxamic acid; trichostatin	bacterial metabolite; EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector
s-adenosyl-1,12-diamino-3-thio-9-azadodecane S-adenosyl-1,12-diamino-3-thio-9-azadodecane: structure given in first source	3.1	1
mitoguazone Mitoguazone: Antineoplastic agent effective against myelogenous leukemia in experimental animals. Also acts as an inhibitor of animal S-adenosylmethionine decarboxylase.. mitoguazone : A hydrazone obtained by formal condensation of the two carbonyl groups of methylglyoxal with the primary amino groups of two molecules of aminoguanidine.	3.49	2	guanidines; hydrazone	antineoplastic agent; apoptosis inducer; EC 4.1.1.50 (adenosylmethionine decarboxylase) inhibitor
cgc 11047 CGC 11047: may prove useful in promoting regression of choroidal neovascularization	3.52	2
deferitrin 4'-hydroxydesazadesferrithiocin: structure in first source	2.02	1

Condition	Relationship Strength	Studies
Leukemia L 1210 [description not available]	3.68	10
Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.	2.4	2
Benign Neoplasms, Brain [description not available]	1.99	1
Glial Cell Tumors [description not available]	1.99	1
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	1.99	1
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	1.99	1
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	1.99	1
Opportunistic Infections An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.	2.92	1
Breast Cancer [description not available]	3.61	3
Breast Neoplasms Tumors or cancer of the human BREAST.	3.61	3
Congenital Zika Syndrome [description not available]	2.25	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.25	1
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1
Cancer of Ovary [description not available]	2.42	2
Cystadenocarcinoma A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)	2.02	1
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	2.42	2
Adenocarcinoma, Basal Cell [description not available]	1.98	1
Cancer of Lung [description not available]	3.37	7
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	1.98	1
Lung Neoplasms Tumors or cancer of the LUNG.	3.37	7
Carcinoma, Anaplastic [description not available]	2.67	3
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	2.67	3
Di Guglielmo Disease [description not available]	1.98	1
Leukemia, Erythroblastic, Acute A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood.	1.98	1
Carcinoma, Oat Cell [description not available]	2.9	4
Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)	2.9	4
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	2.38	2
Carcinoma, Non-Small Cell Lung [description not available]	1.98	1
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	1.98	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	1.98	1
Experimental Mammary Neoplasms [description not available]	1.98	1
Malignant Melanoma [description not available]	2.38	2
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	2.38	2
Gastric Ulcer [description not available]	1.97	1
Stomach Ulcer Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).	1.97	1
Cancer of Colon [description not available]	1.97	1
Colonic Neoplasms Tumors or cancer of the COLON.	1.97	1

n(1), n(12)-diethylspermine

Description

Cross-References

Synonyms (29)

Research Excerpts

Dosage Studied

Roles (1)

Drug Classes (4)

Protein Targets (4)

Potency Measurements

Biological Processes (21)

Molecular Functions (8)

Ceullar Components (8)

Bioassays (187)

Research

Studies (50)

Market Indicators

Research Demand Index: 11.12

Study Types

n(1), n(12)-diethylspermine

Description

Cross-References

Synonyms (29)

Research Excerpts

Dosage Studied

Roles (1)

Drug Classes (4)

Protein Targets (4)

Potency Measurements

Biological Processes (21)

Molecular Functions (8)

Ceullar Components (8)

Bioassays (187)

Research

Studies (50)

Market Indicators

Research Demand Index: 11.12

Study Types

Related Drugs (30)

Related Conditions (37)